Pfizer 2014 Annual Report Download - page 58

Download and view the complete annual report

Please find page 58 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 58
ANNUAL REVIEW 2014
Our World > Access to Medicines
We are developing a portfolio of innovative business approaches
as part of our strategy to increase access to our medicines in both
developed and developing countries.
ACCESS TO MEDICINES
EXPANDING ACCESS
TO ESSENTIAL HEALTH CARE
We seek to bring more medicines to more people and to improve health around
the world. Our social investments focus on effective and sustainable health care
delivery for underserved patients, wherever they live, while empowering our
colleagues, strengthening our stakeholder relationships and ultimately having a
positive impact on society and our business.
COMMERCIAL PROGRAMS TO IMPROVE ACCESS
Gavi, the Vaccine Alliance’s
Advance Market Commitment (AMC)
for Pneumococcal Vaccines
Gavi, the Vaccine Alliance’s AMC provides vaccines to the world’s
poorest countries on an accelerated, affordable and sustainable
basis. Pzer has committed to supply up to 740 million doses of
Prevenar 13® through 2025. Prevenar 13 is available in more than
32 Gavi-eligible countries, with many additional launches planned.
We are committed to helping meet the AMC’s primary goal of
reducing morbidity and mortality from pneumococcal disease and,
specically, to prevent an estimated seven million childhood deaths
by 2030.